We conducted a retrospective study at a single center to evaluate the vaccination of LAM patients, the reasons for vaccine hesitancy, vaccine safety and efficacy, and the potential impact of mTOR inhibitors in LAM patients infected with the SARS-CoV-2 Omicron variant. The gene discussed is MTOR; the disease is lymphangioleiomyomatosis.